Molecular diagnosis of prostate cancer: Topical issues

Molecular diagnosis of prostate cancer: Topical issues

Show other versions (1)

Prostate cancer (PC) is the second most common cancer and the fifth highest malignancy mortality rate in men worldwide. Although PC is detectable in 15-20% of men during life, its death risk is only about 3%. This means that not all PC cases require the same management tactics. The given review anal...

Full description

Bibliographic Details
Main Authors: E. N. Knyazev, K. A. Fomicheva, K. M. Nyushko, A. D. Kaprin, B. Ya. Alekseev, M. Yu. Shkurnikov
Format: Article
Language:Russian
Published: ABV-press 2014-12-01
Series:Onkourologiâ
Subjects:
prostate cancer
molecular genetic markers
receptors
membrane proteins
heat shock protein
transcriptome
gene fusion
matrix ribonucleic acids
prostate cancer antigen 3
polymerase chain reaction
expression
hyperactivation
Online Access:https://oncourology.abvpress.ru/oncur/article/view/391
id doaj-a6d7e2d65a57429599aacf969fb17ead
record_format Article
spelling doaj-a6d7e2d65a57429599aacf969fb17ead2021-07-29T08:41:40ZrusABV-pressOnkourologiâ 1726-97761996-18122014-12-01104142210.17650/1726-9776-2014-10-4-14-22406Molecular diagnosis of prostate cancer: Topical issuesE. N. Knyazev0K. A. Fomicheva1K. M. Nyushko2A. D. Kaprin3B. Ya. Alekseev4M. Yu. Shkurnikov5P.A. Herzen Moscow Oncology Research Institute, Ministry of Health of Russia; 3, Second Botkinsky Pr., Moscow 125284P.A. Herzen Moscow Oncology Research Institute, Ministry of Health of Russia; 3, Second Botkinsky Pr., Moscow 125284P.A. Herzen Moscow Oncology Research Institute, Ministry of Health of Russia; 3, Second Botkinsky Pr., Moscow 125284P.A. Herzen Moscow Oncology Research Institute, Ministry of Health of Russia; 3, Second Botkinsky Pr., Moscow 125284P.A. Herzen Moscow Oncology Research Institute, Ministry of Health of Russia; 3, Second Botkinsky Pr., Moscow 125284P.A. Herzen Moscow Oncology Research Institute, Ministry of Health of Russia; 3, Second Botkinsky Pr., Moscow 125284Prostate cancer (PC) is the second most common cancer and the fifth highest malignancy mortality rate in men worldwide. Although PC is detectable in 15-20% of men during life, its death risk is only about 3%. This means that not all PC cases require the same management tactics. The given review analyzes the current investigations searching for molecular biological markers to predict the course of PC and to choose its treatment policy, including that in the development of resistance to androgen-deprivation therapy.https://oncourology.abvpress.ru/oncur/article/view/391prostate cancermolecular genetic markersreceptorsmembrane proteinsheat shock proteintranscriptomegene fusionmatrix ribonucleic acidsprostate cancer antigen 3polymerase chain reactionexpressionhyperactivation
collection DOAJ
language Russian
format Article
sources DOAJ
author E. N. Knyazev
K. A. Fomicheva
K. M. Nyushko
A. D. Kaprin
B. Ya. Alekseev
M. Yu. Shkurnikov
spellingShingle E. N. Knyazev
K. A. Fomicheva
K. M. Nyushko
A. D. Kaprin
B. Ya. Alekseev
M. Yu. Shkurnikov
Molecular diagnosis of prostate cancer: Topical issues
Onkourologiâ
prostate cancer
molecular genetic markers
receptors
membrane proteins
heat shock protein
transcriptome
gene fusion
matrix ribonucleic acids
prostate cancer antigen 3
polymerase chain reaction
expression
hyperactivation
author_facet E. N. Knyazev
K. A. Fomicheva
K. M. Nyushko
A. D. Kaprin
B. Ya. Alekseev
M. Yu. Shkurnikov
author_sort E. N. Knyazev
title Molecular diagnosis of prostate cancer: Topical issues
title_short Molecular diagnosis of prostate cancer: Topical issues
title_full Molecular diagnosis of prostate cancer: Topical issues
title_fullStr Molecular diagnosis of prostate cancer: Topical issues
title_full_unstemmed Molecular diagnosis of prostate cancer: Topical issues
title_sort molecular diagnosis of prostate cancer: topical issues
publisher ABV-press
series Onkourologiâ
issn 1726-9776
1996-1812
publishDate 2014-12-01
description Prostate cancer (PC) is the second most common cancer and the fifth highest malignancy mortality rate in men worldwide. Although PC is detectable in 15-20% of men during life, its death risk is only about 3%. This means that not all PC cases require the same management tactics. The given review analyzes the current investigations searching for molecular biological markers to predict the course of PC and to choose its treatment policy, including that in the development of resistance to androgen-deprivation therapy.
topic prostate cancer
molecular genetic markers
receptors
membrane proteins
heat shock protein
transcriptome
gene fusion
matrix ribonucleic acids
prostate cancer antigen 3
polymerase chain reaction
expression
hyperactivation
url https://oncourology.abvpress.ru/oncur/article/view/391
work_keys_str_mv AT enknyazev moleculardiagnosisofprostatecancertopicalissues
AT kafomicheva moleculardiagnosisofprostatecancertopicalissues
AT kmnyushko moleculardiagnosisofprostatecancertopicalissues
AT adkaprin moleculardiagnosisofprostatecancertopicalissues
AT byaalekseev moleculardiagnosisofprostatecancertopicalissues
AT myushkurnikov moleculardiagnosisofprostatecancertopicalissues
_version_ 1721252606676828160

Similar Items